Background Coronary restenosis after percutaneous coronary intervention still remains a significant problem, despite all medical advances. Unraveling the mechanisms leading to restenosis development remains challenging. Many studies have identified genetic markers associated with restenosis, but consistent replication of the reported markers is scarce. The aim of the current study was to analyze the joined effect of previously in literature reported candidate genes for restenosis in the GENetic DEterminants of Restenosis (GENDER) databank. Methodology/Principal Findings Candidate genes were selected using a MEDLINE search including the terms ‘genetic polymorphism’ and ‘coronary restenosis’. The final set included 36 genes. Subsequently, all single nucleotide polymorphisms (SNPs) in the genomic region of these genes were analyzed in GENDER using set-based analysis in PLINK. The GENDER databank contains genotypic data of 2,571,586 SNPs of 295 cases with restenosis and 571 matched controls. The set, including all 36 literature reported genes, was, indeed, significantly associated with restenosis, p = 0.024 in the GENDER study. Subsequent analyses of the individual genes demonstrated that the observed association of the complete set was determined by 6 of the 36 genes. Conclusion Despite overt inconsistencies in literature, with regard to individual candidate gene studies, this is the first study demonstrating that the joint effect of all these genes together, indeed, is associated with restenosis.
References
[1]
Jukema JW, Verschuren JJ, Ahmed TA, Quax PH (2012) Restenosis after PCI. Part 1: pathophysiology and risk factors. Nat Rev Cardiol 9: 53–62.
[2]
Jukema JW, Ahmed TA, Verschuren JJ, Quax PH (2012) Restenosis after PCI. Part 2: prevention and therapy. Nat Rev Cardiol 9: 79–90.
[3]
Kastrati A, Koch W, Berger PB, Mehilli J, Stephenson K, et al. (2000) Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. J Am Coll Cardiol 36: 2168–2173.
[4]
Koch W, Bottiger C, Mehilli J, von BN, Neumann FJ, et al. (2001) Association of a CD18 gene polymorphism with a reduced risk of restenosis after coronary stenting. Am J Cardiol 88: 1120–1124.
[5]
Monraats PS, Pires NM, Schepers A, Agema WR, Boesten LS, et al. (2005) Tumor necrosis factor-alpha plays an important role in restenosis development. FASEB J 19: 1998–2004.
[6]
Monraats PS, Pires NM, Agema WR, Zwinderman AH, Schepers A, et al. (2005) Genetic inflammatory factors predict restenosis after percutaneous coronary interventions. Circulation 112: 2417–2425.
[7]
Sampietro ML, Trompet S, Verschuren JJ, Talens RP, Deelen J, et al. (2011) A genome-wide association study identifies a region at chromosome 12 as a potential susceptibility locus for restenosis after percutaneous coronary intervention. Hum Mol Genet 20: 4748–4757.
[8]
O’Donnell CJ, Nabel EG (2011) Genomics of cardiovascular disease. N Engl J Med 365: 2098–2109.
[9]
Keating BJ, Tischfield S, Murray SS, Bhangale T, Price TS, et al. (2008) Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS One 3: e3583.
[10]
Ma L, Han S, Yang J, Da Y (2010) Multi-locus test conditional on confirmed effects leads to increased power in genome-wide association studies. PLoS One 5: e15006.
[11]
Agema WR, Monraats PS, Zwinderman AH, de Winter RJ, Tio RA, et al. (2004) Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. Eur Heart J 25: 1163–1170.
[12]
Sampietro ML, Pons D, de Knijff P, Slagboom PE, Zwinderman A, et al. (2009) A genome wide association analysis in the GENDER study. Neth Heart J 17: 262–264.
[13]
Li Y, Willer CJ, Ding J, Scheet P, Abecasis GR (2010) MaCH: using sequence and genotype data to estimate haplotypes and unobserved genotypes. Genet Epidemiol 34: 816–834.
[14]
Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, et al. (2007) PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559–575.
[15]
Biocarta website. Biocarta pathway. Available: http://www.biocarta.com/pathfiles/h_vdrp？athway.asp.Accessed 2012 Mar 1..
[16]
Fridley BL, Biernacka JM (2011) Gene set analysis of SNP data: benefits, challenges, and future directions. Eur J Hum Genet 19: 837–843.
[17]
Torkamani A, Topol EJ, Schork NJ (2008) Pathway analysis of seven common diseases assessed by genome-wide association. Genomics 92: 265–272.
[18]
Gui H, Li M, Sham PC, Cherny SS (2011) Comparisons of seven algorithms for pathway analysis using the WTCCC Crohn’s Disease dataset. BMC Res Notes 4: 386.
[19]
Deelen J, Uh HW, Monajemi R, van HD, Thijssen PE, et al. (2011) Gene set analysis of GWAS data for human longevity highlights the relevance of the insulin/IGF-1 signaling and telomere maintenance pathways. Age (Dordr ) In press. 10.1007/s11357–011–9340–3 [doi].
[20]
Swapna N, Vamsi UM, Usha G, Padma T (2011) Risk conferred by FokI polymorphism of vitamin D receptor (VDR) gene for essential hypertension. Indian J Hum Genet 17: 201–206.
[21]
Kolz M, Baumert J, Gohlke H, Grallert H, Doring A, et al. (2009) Association study between variants in the fibrinogen gene cluster, fibrinogen levels and hypertension: results from the MONICA/KORA study. Thromb Haemost 101: 317–324.
[22]
Niu W, Qi Y (2010) Association of the angiotensin II type I receptor gene +1166 A>C polymorphism with hypertension risk: evidence from a meta-analysis of 16474 subjects. Hypertens Res 33: 1137–1143.
[23]
Mansego ML, Solar GM, Alonso MP, Martinez F, Saez GT, et al. (2011) Polymorphisms of antioxidant enzymes, blood pressure and risk of hypertension. J Hypertens 29: 492–500.
[24]
Falcone C, Emanuele E, Buzzi MP, Ballerini L, Repetto A, et al. (2007) The-374T/A variant of the rage gene promoter is associated with clinical restenosis after coronary stent placement. Int J Immunopathol Pharmacol 20: 771–777.
[25]
Shim CY, Park S, Yoon SJ, Park HY, Kim HT, et al. (2007) Association of RAGE gene polymorphisms with in-stent restenosis in non-diabetic Korean population. Cardiology 107: 261–268.
[26]
Gross CM, Perrot A, Geier C, Posch MG, Hassfeld S, et al. (2007) Recurrent in-stent restenosis is not associated with the angiotensin-converting enzyme D/I, angiotensinogen Thr174Met and Met235Thr, and the angiotensin-II receptor 1 A1166C polymorphism. J Invasive Cardiol 19: 261–264.
[27]
Wijpkema JS, van Haelst PL, Monraats PS, Bruinenberg M, Zwinderman AH, et al. (2006) Restenosis after percutaneous coronary intervention is associated with the angiotensin-II type-1 receptor 1166A/C polymorphism but not with polymorphisms of angiotensin-converting enzyme, angiotensin-II receptor, angiotensinogen or heme oxygenase-1. Pharmacogenet Genomics 16: 331–337.
[28]
Oguri M, Kato K, Hibino T, Yokoi K, Segawa T, et al. (2007) Genetic risk for restenosis after coronary stenting. Atherosclerosis 194: e172–e178.
[29]
Shimada K, Miyauchi K, Mokuno H, Watanabe Y, Iwama Y, et al. (2004) Promoter polymorphism in the CD14 gene and concentration of soluble CD14 in patients with in-stent restenosis after elective coronary stenting. Int J Cardiol 94: 87–92.
[30]
Tiroch K, Koch W, Mehilli J, Bottiger C, Schomig A, et al. (2009) P27 and P53 gene polymorphisms and restenosis following coronary implantation of drug-eluting stents. Cardiology 112: 263–269.
[31]
van Tiel CM, Bonta PI, Rittersma SZ, Beijk MA, Bradley EJ, et al. (2009) p27kip1-838C>A single nucleotide polymorphism is associated with restenosis risk after coronary stenting and modulates p27kip1 promoter activity. Circulation 120: 669–676.
[32]
Oguri M, Kato K, Hibino T, Yokoi K, Segawa T, et al. (2007) Identification of a polymorphism of UCP3 associated with recurrent in-stent restenosis of coronary arteries. Int J Mol Med 20: 533–538.
[33]
Niessner A, Marculescu R, Kvakan H, Haschemi A, Endler G, et al. (2005) Fractalkine receptor polymorphisms V2491 and T280M as genetic risk factors for restenosis. Thromb Haemost 94: 1251–1256.
[34]
Horibe H, Yamada Y, Ichihara S, Watarai M, Yanase M, et al. (2004) Genetic risk for restenosis after coronary balloon angioplasty. Atherosclerosis 174: 181–187.
[35]
Tiroch KA, Sibbing D, Koch W, Roosen-Runge T, Mehilli J, et al. (2010) Protective effect of the CYP2C19 *17 polymorphism with increased activation of clopidogrel on cardiovascular events. Am Heart J 160: 506–512.
[36]
Monraats PS, Rana JS, Zwinderman AH, de Maat MP, Kastelein JP, et al. (2005) -455G/A polymorphism and preprocedural plasma levels of fibrinogen show no association with the risk of clinical restenosis in patients with coronary stent placement. Thromb Haemost 93: 564–569.
[37]
Pons D, Monraats PS, de Maat MP, Pires NM, Quax PH, et al. (2007) The influence of established genetic variation in the haemostatic system on clinical restenosis after percutaneous coronary interventions. Thromb Haemost 98: 1323–1328.
[38]
Martinez-Rios MA, Pena-Duque MA, Fragoso JM, Delgadillo-Rodriguez H, Rodriguez-Perez JM, et al. (2009) Tumor necrosis factor alpha and interleukin 10 promoter polymorphisms in Mexican patients with restenosis after coronary stenting. Biochem Genet 47: 707–716.
[39]
Koch W, Tiroch K, von BN, Schomig A, Kastrati A (2003) Tumor necrosis factor-alpha, lymphotoxin-alpha, and interleukin-10 gene polymorphisms and restenosis after coronary artery stenting. Cytokine 24: 161–171.
[40]
Monraats PS, Kurreeman FA, Pons D, Sewgobind VD, de Vries FR, et al. (2007) Interleukin 10: a new risk marker for the development of restenosis after percutaneous coronary intervention. Genes Immun 8: 44–50.
[41]
Marculescu R, Mlekusch W, Exner M, Sabeti S, Michor S, et al. (2003) Interleukin-1 cluster combined genotype and restenosis after balloon angioplasty. Thromb Haemost 90: 491–500.
[42]
Zee RY, Fernandez-Ortiz A, Macaya C, Pintor E, Fernandez-Cruz A, et al. (2003) IL-1 cluster genes and occurrence of post-percutaneous transluminal coronary angioplasty restenosis: a prospective, angiography-based evaluation. Atherosclerosis 171: 259–264.
[43]
Monraats PS, Rana JS, Nierman MC, Pires NM, Zwinderman AH, et al. (2005) Lipoprotein lipase gene polymorphisms and the risk of target vessel revascularization after percutaneous coronary intervention. J Am Coll Cardiol 46: 1093–1100.
[44]
Chung SL, Chiou KR, Charng MJ (2006) 677TT polymorphism of methylenetetrahydrofolate reductase in combination with low serum vitamin B12 is associated with coronary in-stent restenosis. Catheter Cardiovasc Interv 67: 349–355.
[45]
Koch W, Ndrepepa G, Mehilli J, Braun S, Burghartz M, et al. (2003) Homocysteine status and polymorphisms of methylenetetrahydrofolate reductase are not associated with restenosis after stenting in coronary arteries. Arterioscler Thromb Vasc Biol 23: 2229–2234.
[46]
Gomma AH, Elrayess MA, Knight CJ, Hawe E, Fox KM, et al. (2002) The endothelial nitric oxide synthase (Glu298Asp and-786T>C) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J 23: 1955–1962.
[47]
Pons D, Monraats PS, Zwinderman AH, de Maat MP, Doevendans PA, et al. (2009) Metabolic background determines the importance of NOS3 polymorphisms in restenosis after percutaneous coronary intervention: A study in patients with and without the metabolic syndrome. Dis Markers 26: 75–83.
[48]
Gorchakova O, Koch W, von BN, Mehilli J, Schomig A, et al. (2003) Association of a genetic variant of endothelial nitric oxide synthase with the 1 year clinical outcome after coronary stent placement. Eur Heart J 24: 820–827.
[49]
Rudez G, Pons D, Leebeek F, Monraats P, Schrevel M, et al. (2008) Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions. Hum Mutat 29: 375–380.
[50]
Bottiger C, Koch W, Lahn C, Mehilli J, von BN, et al. (2003) 4G/5G polymorphism of the plasminogen activator inhibitor-1 gene and risk of restenosis after coronary artery stenting. Am Heart J 146: 855–861.
[51]
Pons D, Trompet S, de Craen AJ, Thijssen PE, Quax PH, et al. (2011) Genetic variation in PCAF, a key mediator in epigenetics, is associated with reduced vascular morbidity and mortality: evidence for a new concept from three independent prospective studies. Heart 97: 143–150.
[52]
Neugebauer P, Goldbergova-Pavkova M, Kala P, Bocek O, Jerabek P, et al. (2009) Nuclear receptors gene polymorphisms and risk of restenosis and clinical events following coronary stenting. Vnitr Lek 55: 1135–1140.
[53]
Koch W, Jung V, von BN, Schomig A, Kastrati A (2004) Peroxisome proliferator-activated receptor gamma gene polymorphisms and restenosis in diabetic patients after stenting in coronary arteries. Diabetologia 47: 1126–1127.
[54]
Rittersma SZ, Boekholdt SM, Koch KT, Geuzebroek R, Bax M, et al. (2004) Thrombospondin gene polymorphisms and the risk of angiographic coronary in-stent restenosis. Am J Med 116: 499–500.
[55]
Kojima S, Iwai N, Tago N, Ono K, Ohmi K, et al. (2004) p53Arg72Pro polymorphism of tumour suppressor protein is associated with luminal narrowing after coronary stent placement. Heart 90: 1069–1070.
[56]
Zee RY, Cook NR, Kim CA, Fernandez-Cruz A, Lindpaintner K (2004) TP53 haplotype-based analysis and incidence of post-angioplasty restenosis. Hum Genet 114: 386–390.
[57]
Monraats PS, Fang Y, Pons D, Pires NM, Pols HA, et al. (2010) Vitamin D receptor: a new risk marker for clinical restenosis after percutaneous coronary intervention. Expert Opin Ther Targets 14: 243–251.
